BioMarin Set Sights On Pivotal Gene Therapy Hemophilia Study
Promising early data for BioMarin’s investigational gene therapy for hemophilia, BMN 270, could suggest it could “normalize life” for patients.
Promising early data for BioMarin’s investigational gene therapy for hemophilia, BMN 270, could suggest it could “normalize life” for patients.